(Q72524218)
Statements
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer (English)
S Iacobelli
C Garufi
L Irtelli
M T Martino
F Santobuono
G Vicario
N Tinari
B Fiorentino
P Innocenti
1 February 1995